Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pentacel: HCPDT-IPV/PRP-T Vaccine and Prevnar · 1 trial · 5 indications
Seroconversion was defined as the percentage of subjects with ≥ 4-fold post-dose 3 for anti-pertussis and ≥ 0.15 μg/mL or ≥ 1.0 μg/mL for anti-Polyribosylribitol Phosphate (PRP) responses.
Anti-pertussis response include antibodies to Pertussis Toxoid (PT); Filamentous Haemagglutinin (FHA); Fimbriae Types 2 and 3 (FIM) and Pertactin (PRN) antigens.
| Arm | Type | Description |
|---|---|---|
| Pentacel™ concurrently with Prevnar® | EXPERIMENTAL | Participants had Pentacel™ concurrently administered with Prevnar® |
| Pentacel™ staggered schedule with Prevnar® | EXPERIMENTAL | Participants had Pentacel™ given at different times from Prevnar® (using a standardized, staggered schedule). |
| Name | Type | Description |
|---|---|---|
| Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar® | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria : * Healthy infants 2 months (≥ 42 days and ≤ 89 days) of age. * Infants with at least 36 weeks of gestation at delivery. * Must have received 1 dose of Hepatitis B vaccine (with that dose at least 15 days before the administration of study vaccines). * Able to attend the schedul...
Pentacel: HCPDT-IPV/PRP-T Vaccine and Prevnar is used for diphtheria, tetanus, Haemophilus infection, pertussis, and polio. It is an investigational combination vaccine being studied in the infectious disease therapeutic area. The drug is currently in Phase 3 clinical development.
Sanofi (ticker: SNY) is developing Pentacel: HCPDT-IPV/PRP-T Vaccine and Prevnar. The company is conducting clinical trials for this vaccine candidate, which is being studied for the prevention of diphtheria, tetanus, Haemophilus infection, pertussis, and polio.
Pentacel: HCPDT-IPV/PRP-T Vaccine and Prevnar is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed, with a total enrollment of 1,167 participants.
Pentacel: HCPDT-IPV/PRP-T Vaccine and Prevnar has one completed Phase 3 trial, NCT00772928, titled 'Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™'. The trial enrolled 1,167 participants in the United States, including healthy volunteers aged 42 days and older.
Pentacel: HCPDT-IPV/PRP-T Vaccine and Prevnar is a combination vaccine that includes both Pentacel (HCPDT-IPV/PRP-T) and Prevnar (pneumococcal conjugate vaccine). The clinical trial NCT00772928 studied the effect of Prevnar on the immunogenicity of Pentacel, indicating they are separate vaccine components studied together.